Relationship between phenolic glycolipid antigen (PGL-I) and leprosy detection
DOI:
https://doi.org/10.33448/rsd-v12i3.40664Keywords:
Glycolipids; Leprosy; Early diagnosis.Abstract
Understand the advantages and disadvantages of the phenolic glycolipid antigen in the early detection of leprosy. This research consists of an integrative review of the literature, for the search the guiding question was elaborated using the necessary subsidies to enable the location of the studies available in the databases: “What is the relationship between the phenolic glycolipid antigen and the aid in the diagnosis of leprosy ?”. The databases used were: National Library of Medicine National Institutes of Health (PubMed), Science Direct and Virtual Health Library (BVS/MEDLINE). The descriptors and keywords were obtained by consulting the Health Sciences Descriptors (DECS) and Medical Subject Headings (MeSH), the descriptors were “phenolic glycolipid I”, “leprosy”, “diagnosis”, “leprosy” and “diagnosis”. ”. The study had a sample of 8 articles, among which negative and positive aspects of the phenolic glycolipid antigen for the detection of leprosy were discussed. Among them, it was positively listed that the antigen helps to indicate the early diagnosis of the disease, indicates its potential to develop more severe reactions, as well as helps the diagnosis and predicts relapses, while the negative points listed were the low ability to detect true positives, diagnostic insufficiency and impossibility of initiating therapy due to indicating only previous infection. It is clear that more studies are needed on the functionality of the phenolic glycolipid antigen (PGL-I) in the early detection of leprosy, due to the high dichotomy between negative and positive aspects.
References
Abbas, A K.; Pillai, S; Lichtman, A H. (2019). Imunologia:Celular e Molecular. (9a ed.). Editora Elsevier Ltda,
Araújo, A. E. R. D. A., Aquino, D. M. C. D., Goulart, I. M. B., Pereira, S. R. F., Figueiredo, I. A., Serra, H. O., ... & Caldas, A. D. J. M. (2014). Complicações neurais e incapacidades em hanseníase em capital do nordeste brasileiro com alta endemicidade. Revista brasileira de epidemiologia, 17, 899-910.
Arenas, N. E., Pieffet, G., Rocha-Roa, C., & Guerrero, M. I. (2022). Design of a specific peptide against phenolic glycolipid-1 from Mycobacterium leprae and its implications in leprosy bacilli entry. Memórias do Instituto Oswaldo Cruz, 117.
Bernardes-Filho, F., Lima, F. R., Voltan, G., Paula, N. A. D., & Frade, M. A. C. (2021). Leprosy case series in the emergency room: A warning sign for a challenging diagnosis. Brazilian Journal of Infectious Diseases, 25.
Bovolini, G. M., Silva, E. A., & de Souza, V. N. B. (2019). Desempenho dos antígenos PGL-1, LID-1 e NDO-LID para diagnóstico sorológico de hanseníase em pacientes e contatos domiciliares: revisão de literatura. Hansenologia Internationalis: hanseníase e outras doenças infecciosas, 44, 1-14.
Devides, A. C., Rosa, P. S., Belone, A. D. F. F., Coelho, N. M. B., Ura, S., & Silva, E. A. (2018). Can anti–PGL-1 and anti–NDO-LID-1 antibody titers be used to predict the risk of reactions in leprosy patients?. Diagnostic Microbiology and Infectious Disease, 91(3), 260-265.
Fracarolli, I. F. L., Oliveira, S. A. D., & Marziale, M. H. P. (2017). Colonização bacteriana e resistência antimicrobiana em trabalhadores de saúde: revisão integrativa. Acta Paulista de Enfermagem, 30, 651-657.
Guia prático sobre a hanseníase [recurso eletrônico] / Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância das Doenças Transmissíveis. – Brasília: Ministério da Saúde, 2017. 68 p. : il.
Hambridge, T., Nanjan Chandran, S. L., Geluk, A., Saunderson, P., & Richardus, J. H. (2021). Mycobacterium leprae transmission characteristics during the declining stages of leprosy incidence: a systematic review. PLoS Neglected Tropical Diseases, 15(5), e0009436.
Leturiondo, A. L., Noronha, A. B., do Nascimento, M. O. O., Ferreira, C. D. O., Rodrigues, F. D. C., Moraes, M. O., & Talhari, C. (2019). Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil. BMC infectious diseases, 19(1), 1-6.
Melnyk, B. M., & Fineout-Overholt, E. (2022). Evidence-based practice in nursing & healthcare: A guide to best practice. Lippincott Williams & Wilkins.
Menezes, V. M., Guedes, J. C. R., de Albuquerque Fernandes, L. S., de Mello Haddad, N., Lima, R. B., Martins, E. S., & Martins, C. J. (2019). Perfil clínico-epidemiológico de pacientes com hanseníase atendidos em hospital universitário no Rio de Janeiro entre 2008 e 2017. Medicina (Ribeirão Preto), 52(1), 7-15.
Muñoz, M., Beltrán-Alzate, J. C., Duthie, M. S., Serrano-Coll, H., & Cardona-Castro, N. (2018). Comparison of enzyme-linked immunosorbent assay using either natural octyl disaccharide-leprosy IDRI diagnostic or phenolic glycolipid-I antigens for the detection of leprosy patients in Colombia. The American Journal of Tropical Medicine and Hygiene, 98(1), 274.
Niitsuma, E. N. A., Bueno, I. D. C., Arantes, E. O., Carvalho, A. P. M., Xavier Junior, G. F., Fernandes, G. D. R., & Lana, F. C. F. (2021). Factors associated with the development of leprosy in contacts: a systematic review and meta-analysis. Revista Brasileira de Epidemiologia, 24.
Oliveira, A. L. G., Fraga, V. G., Sernizon-Guimarães, N., Cardoso, M. S., Viana, A. G., Bueno, L. L., ... & Fujiwara, R. T. (2020). Diagnostic accuracy of tests using recombinant protein antigens of Mycobacterium leprae for leprosy: A systematic review. Journal of infection and public health, 13(8), 1078-1088.
Richardus, R. A., van der Zwet, K., van Hooij, A., Wilson, L., Oskam, L., Faber, R., ... & Geluk, A. (2017). Longitudinal assessment of anti-PGL-I serology in contacts of leprosy patients in Bangladesh. PLoS neglected tropical diseases, 11(12), e0006083.
Santos, A. R., & Ignotti, E. (2020). Prevencao de incapacidade fisica por hanseniase no Brasil: análise historica/Prevention of physical disabilities due to leprosy in Brazil: a historic analysis. Ciência & Saúde Coletiva, 25(10), 3731-3745.
Santos, S. M. F., de Sousa, M. T., dos Santos, L. A., da Silva Jacob, L. M., Cristiane, M., Figueira, S., & de Melo, M. C. (2018). Perfil Epidemiológico e Percepção sobre a Hanseníase em Menores de 15 anos no Município de Santarém-PA. Journal of Health Sciences, 20(1), 61-67.
Silva, M. B., Li, W., Bouth, R. C., Gobbo, A. R., Messias, A. C. C., Moraes, T. M. P., ... & Spencer, J. S. (2021). Latent leprosy infection identified by dual RLEP and antígeno glicolipídeo fenólico positivity: Implications for new control strategies. Plos one, 16(5), e0251631.
Silva, R. A. D., Oliveira, B. N. L. D., Silva, L. P. A. D., Oliveira, M. A., & Chaves, G. C. (2020). Resistência a Antimicrobianos: a formulação da resposta no âmbito da saúde global. Saúde em Debate, 44, 607-623.
Tió-Coma, M., Kiełbasa, S. M., van den Eeden, S. J., Mei, H., Roy, J. C., Wallinga, J., ... & Geluk, A. (2021). Blood RNA signature RISK4LEP predicts leprosy years before clinical onset. EBioMedicine, 68, 103379.
Torres, D. C., Pinho, K. S., Borges, C. K. S., Lopes, A. B., Costa, G. P., & Gonçalves, M. C. (2019). Comparação da qualidade de vida de indivíduos com e sem hanseníase. Revista Ceuma Perspectivas, 30(3), 64-77.
Valéria, P, (2021). Dermatologia Prática. Grupo GEN, 2009. 978-85-277-2015-1. https://integrada.minhabiblioteca.com.br/#/books/978-85-277-2015-1/.
van Hooij, A., van den Eeden, S., Richardus, R., Fat, E. T. K., Wilson, L., Franken, K. L., ... & Geluk, A. (2019). Application of new host biomarker profiles in quantitative point-of-care tests facilitates leprosy diagnosis in the field. EBioMedicine, 47, 301-308.
van Hooij, A., van den Eeden, S. J., Khatun, M., Soren, S., Franken, K. L., Roy, J. C., ... & Geluk, A. (2021). BCG-induced immunity profiles in household contacts of leprosy patients differentiate between protection and disease. Vaccine, 39(50), 7230-7237.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Giovanna Santana Machado; Sarah Neres Mendes; Roberto da Silva Almeida Junior
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
